NO975585L - C-4' modifiserte adenosin-kinase inhibitorer - Google Patents
C-4' modifiserte adenosin-kinase inhibitorerInfo
- Publication number
- NO975585L NO975585L NO975585A NO975585A NO975585L NO 975585 L NO975585 L NO 975585L NO 975585 A NO975585 A NO 975585A NO 975585 A NO975585 A NO 975585A NO 975585 L NO975585 L NO 975585L
- Authority
- NO
- Norway
- Prior art keywords
- kinase inhibitors
- adenosine kinase
- modified adenosine
- adenosine
- substituents
- Prior art date
Links
- 239000003121 adenosine kinase inhibitor Substances 0.000 title abstract 4
- OOXNYFKPOPJIOT-UHFFFAOYSA-N 5-(3-bromophenyl)-7-(6-morpholin-4-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-4-amine;dihydrochloride Chemical class Cl.Cl.C=12C(N)=NC=NC2=NC(C=2C=NC(=CC=2)N2CCOCC2)=CC=1C1=CC=CC(Br)=C1 OOXNYFKPOPJIOT-UHFFFAOYSA-N 0.000 title 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000003843 furanosyl group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 229940127073 nucleoside analogue Drugs 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 239000002718 pyrimidine nucleoside Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/486,161 US5674998A (en) | 1989-09-15 | 1995-06-07 | C-4' modified adenosine kinase inhibitors |
| PCT/US1996/010404 WO1996040705A1 (en) | 1995-06-07 | 1996-06-07 | C-4' modified adenosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO975585D0 NO975585D0 (no) | 1997-12-03 |
| NO975585L true NO975585L (no) | 1998-02-05 |
Family
ID=23930844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO975585A NO975585L (no) | 1995-06-07 | 1997-12-03 | C-4' modifiserte adenosin-kinase inhibitorer |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5674998A (cs) |
| EP (1) | EP0832091B1 (cs) |
| JP (1) | JPH11507387A (cs) |
| KR (1) | KR19990022740A (cs) |
| CN (1) | CN1190401A (cs) |
| AP (1) | AP9701165A0 (cs) |
| AT (1) | ATE257841T1 (cs) |
| AU (1) | AU6178396A (cs) |
| BG (1) | BG102163A (cs) |
| BR (1) | BR9609013A (cs) |
| CA (1) | CA2220642A1 (cs) |
| CZ (1) | CZ392797A3 (cs) |
| DE (1) | DE69631330T2 (cs) |
| EA (1) | EA199800009A1 (cs) |
| HU (1) | HUP9802193A3 (cs) |
| IL (1) | IL122335A0 (cs) |
| IS (1) | IS4621A (cs) |
| MX (1) | MX9709859A (cs) |
| NO (1) | NO975585L (cs) |
| OA (1) | OA10639A (cs) |
| PL (1) | PL323904A1 (cs) |
| SK (1) | SK166097A3 (cs) |
| TR (1) | TR199701539T1 (cs) |
| WO (1) | WO1996040705A1 (cs) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2109796T3 (es) * | 1994-05-03 | 1998-01-16 | Ciba Geigy Ag | Derivados de pirrolopirimidilo con efecto antiproliferante. |
| US6140332A (en) * | 1995-07-06 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
| US6051578A (en) * | 1996-02-12 | 2000-04-18 | Pfizer Inc. | Pyrazolopyrimidines for treatment of CNS disorders |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| YU25500A (sh) * | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| AU769578B2 (en) * | 1999-08-27 | 2004-01-29 | Icn Pharmaceuticals, Inc. | Pyrrolo(2,3-d)pyrimidine nucleoside analogs |
| US6831069B2 (en) | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
| ATE247657T1 (de) | 1999-09-17 | 2003-09-15 | Basf Ag | Pyrazolopyrimidine als arzneimittel |
| US7071199B1 (en) | 1999-09-17 | 2006-07-04 | Abbott Gmbh & Cco. Kg | Kinase inhibitors as therapeutic agents |
| JP2003516962A (ja) * | 1999-12-16 | 2003-05-20 | アルコン，インコーポレイテッド | 視神経損傷および網膜損傷の処置のためのアデノシンキナーゼのインヒビター |
| KR100517163B1 (ko) * | 2000-02-10 | 2005-09-26 | 미쯔이카가쿠 가부시기가이샤 | 1-인산화 당유도체 아노머의 선택적인 제조방법 및뉴클레오사이드의 제조방법 |
| US7638496B2 (en) | 2000-02-15 | 2009-12-29 | Valeant Pharmaceuticals North America | Nucleoside analogs with carboxamidine modified monocyclic base |
| US7414036B2 (en) * | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| AU2002951247A0 (en) * | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| BRPI0400869B8 (pt) * | 2004-03-02 | 2021-05-25 | Univ Estadual Campinas Unicamp | novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases |
| JP2008520744A (ja) | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
| DK1848718T3 (da) | 2005-02-04 | 2012-08-27 | Millennium Pharm Inc | E1 aktiveringsenzymhæmmere |
| BRPI0615157A2 (pt) * | 2005-08-12 | 2016-09-13 | Merck & Co Inc | composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto |
| KR101450535B1 (ko) | 2006-02-02 | 2014-10-14 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｅ１ 활성화 효소의 억제제 |
| AU2007233302C1 (en) | 2006-04-04 | 2013-06-06 | The Regents Of The University Of California | Kinase antagonists |
| WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| WO2009088986A1 (en) | 2008-01-04 | 2009-07-16 | Intellikine, Inc. | Certain chemical entities, compositions and methods |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| EP2252293B1 (en) | 2008-03-14 | 2018-06-27 | Intellikine, LLC | Kinase inhibitors and methods of use |
| BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| JP5819195B2 (ja) | 2008-10-16 | 2015-11-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 融合環ヘテロアリールキナーゼ阻害剤 |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| EP2427195B1 (en) | 2009-05-07 | 2019-05-01 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| CN102421780A (zh) | 2009-05-14 | 2012-04-18 | 米伦纽姆医药公司 | 氨基磺酸((1s，2s，4r)-4-{4-[(1s)-2，3-二氢-1h-茚-1-基氨基]-7h-吡咯并[2，3-d]嘧啶-7-基}-2-羟基环戊基)甲酯盐酸盐 |
| US8927513B2 (en) | 2009-07-07 | 2015-01-06 | Alnylam Pharmaceuticals, Inc. | 5′ phosphate mimics |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環化合物及びその使用 |
| NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| CN103491962B (zh) | 2011-02-23 | 2016-10-12 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| JP6027611B2 (ja) | 2011-07-19 | 2016-11-16 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 複素環式化合物及びその使用 |
| HK1198443A1 (en) | 2011-07-19 | 2015-04-24 | 无限药品股份有限公司 | Heterocyclic compounds and uses thereof |
| WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| AU2012341028C1 (en) | 2011-09-02 | 2017-10-19 | Mount Sinai School Of Medicine | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
| EA035493B1 (ru) | 2011-12-22 | 2020-06-25 | Янссен Байофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| NZ702571A (en) | 2012-06-29 | 2017-02-24 | Pfizer | 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| CA2886240A1 (en) | 2012-09-26 | 2014-04-03 | The Regents Of The University Of California | Modulation of ire1 |
| SMT201800561T1 (it) | 2012-11-01 | 2018-11-09 | Infinity Pharmaceuticals Inc | Trattamento di cancri usando modulatori di isoforme di pi3 chinasi |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| JP6453322B2 (ja) | 2013-06-26 | 2019-01-16 | アリオス バイオファーマ インク． | 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体 |
| US9359365B2 (en) | 2013-10-04 | 2016-06-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EA201690526A1 (ru) | 2013-10-11 | 2017-02-28 | Алиос Биофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
| WO2015092592A1 (en) | 2013-12-17 | 2015-06-25 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| JP6701088B2 (ja) | 2014-03-19 | 2020-05-27 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物 |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| EP3212201B1 (en) | 2014-10-28 | 2022-10-19 | BCI Pharma | Nucleoside kinase inhibitors |
| EA201890454A1 (ru) | 2015-08-06 | 2018-07-31 | Чимерикс, Инк. | Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств |
| EP4585268A3 (en) | 2015-09-14 | 2025-10-15 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| SG10201912456RA (en) | 2016-06-24 | 2020-02-27 | Infinity Pharmaceuticals Inc | Combination therapies |
| WO2019060692A1 (en) | 2017-09-21 | 2019-03-28 | Chimerix, Inc. | MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES |
| PE20221034A1 (es) | 2019-08-08 | 2022-06-17 | B C I Pharma | Derivados de quinolina como inhibidores de proteina quinasa |
| CN115151550B (zh) * | 2019-12-23 | 2024-11-22 | 桑福德·伯纳姆·普雷比医学发现研究所 | 外核苷酸焦磷酸酶/磷酸二酯酶1(enpp1)调节剂及其用途 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CA3171648A1 (en) | 2020-02-18 | 2021-08-26 | Gilead Sciences, Inc. | Antiviral compounds |
| AU2022256476B2 (en) | 2021-04-16 | 2025-06-05 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| KR102639275B1 (ko) * | 2021-06-08 | 2024-02-21 | 퓨쳐메디신 주식회사 | 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물 |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4455420A (en) * | 1983-01-13 | 1984-06-19 | Hoffmann-La Roche Inc. | 4-Amino-7-(5-deoxy-beta-D-ribofuranosyl)-5-iodo-7H-pyrrolo[2,3-d] pyrimidine |
| DE3712735A1 (de) * | 1987-04-15 | 1988-11-10 | Boehringer Mannheim Gmbh | Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel |
| AU665184B2 (en) * | 1991-01-23 | 1995-12-21 | Gensia, Inc. | Adenosine kinase inhibitors |
| FI933303A7 (fi) * | 1991-01-23 | 1993-08-31 | Gensia Inc | Adenosiinikinaasi-inhibiittoreita |
| IL108523A0 (en) * | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
| WO1994018215A1 (en) * | 1993-02-03 | 1994-08-18 | Gensia, Inc. | Adenosine kinase inhibitors comprising lyxofuranosyl derivatives |
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
-
1995
- 1995-06-07 US US08/486,161 patent/US5674998A/en not_active Expired - Fee Related
-
1996
- 1996-06-07 HU HU9802193A patent/HUP9802193A3/hu unknown
- 1996-06-07 SK SK1660-97A patent/SK166097A3/sk unknown
- 1996-06-07 KR KR1019970709182A patent/KR19990022740A/ko not_active Withdrawn
- 1996-06-07 AT AT96919442T patent/ATE257841T1/de not_active IP Right Cessation
- 1996-06-07 PL PL96323904A patent/PL323904A1/xx unknown
- 1996-06-07 CN CN96195383A patent/CN1190401A/zh active Pending
- 1996-06-07 CZ CZ973927A patent/CZ392797A3/cs unknown
- 1996-06-07 DE DE69631330T patent/DE69631330T2/de not_active Expired - Fee Related
- 1996-06-07 IL IL12233596A patent/IL122335A0/xx unknown
- 1996-06-07 AU AU61783/96A patent/AU6178396A/en not_active Abandoned
- 1996-06-07 WO PCT/US1996/010404 patent/WO1996040705A1/en not_active Ceased
- 1996-06-07 CA CA002220642A patent/CA2220642A1/en not_active Abandoned
- 1996-06-07 JP JP9502290A patent/JPH11507387A/ja not_active Ceased
- 1996-06-07 EA EA199800009A patent/EA199800009A1/ru unknown
- 1996-06-07 AP APAP/P/1997/001165A patent/AP9701165A0/en unknown
- 1996-06-07 EP EP96919442A patent/EP0832091B1/en not_active Expired - Lifetime
- 1996-06-07 BR BR9609013-8A patent/BR9609013A/pt unknown
- 1996-06-07 TR TR97/01539T patent/TR199701539T1/xx unknown
-
1997
- 1997-11-26 IS IS4621A patent/IS4621A/is unknown
- 1997-12-03 OA OA70150A patent/OA10639A/en unknown
- 1997-12-03 NO NO975585A patent/NO975585L/no unknown
- 1997-12-08 MX MX9709859A patent/MX9709859A/es unknown
-
1998
- 1998-01-07 BG BG102163A patent/BG102163A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0832091A1 (en) | 1998-04-01 |
| CA2220642A1 (en) | 1996-12-19 |
| PL323904A1 (en) | 1998-04-27 |
| BR9609013A (pt) | 1999-12-14 |
| HUP9802193A3 (en) | 1999-10-28 |
| AP9701165A0 (en) | 1998-01-31 |
| IS4621A (is) | 1997-11-26 |
| ATE257841T1 (de) | 2004-01-15 |
| IL122335A0 (en) | 1998-04-05 |
| US5674998A (en) | 1997-10-07 |
| MX9709859A (es) | 1998-08-30 |
| TR199701539T1 (xx) | 1998-04-21 |
| AU6178396A (en) | 1996-12-30 |
| HUP9802193A2 (hu) | 1999-05-28 |
| JPH11507387A (ja) | 1999-06-29 |
| DE69631330D1 (de) | 2004-02-19 |
| BG102163A (en) | 1998-10-30 |
| OA10639A (en) | 2002-09-17 |
| NO975585D0 (no) | 1997-12-03 |
| CN1190401A (zh) | 1998-08-12 |
| EA199800009A1 (ru) | 1998-06-25 |
| DE69631330T2 (de) | 2004-10-28 |
| WO1996040705A1 (en) | 1996-12-19 |
| SK166097A3 (en) | 1999-06-11 |
| KR19990022740A (ko) | 1999-03-25 |
| EP0832091B1 (en) | 2004-01-14 |
| CZ392797A3 (cs) | 1999-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO975585L (no) | C-4' modifiserte adenosin-kinase inhibitorer | |
| ATE296309T1 (de) | Wasserlösliche adenosin kinase inhibitoren | |
| ATE282628T1 (de) | Oral aktive adenosinkinase-inhibitoren | |
| Hao et al. | Factors determining the activity of 2', 3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. | |
| Carson et al. | Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase (s) | |
| Balzarini et al. | 2', 3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. | |
| Brink et al. | Metabolism and distribution of 9-β-D-arabinofuranosyladenine in mouse tissues | |
| EP0653439A3 (de) | Stabilisierte Oligonucleotide und deren Verwendung. | |
| NO932289L (no) | 2'-deoksy-2',2'-difluor(4-substituerte pyrimidin)nukleosider med antiviralog anticanceraktivitet og mellomprodukter | |
| Uberti et al. | The effect of nucleosides and deoxycoformycin on adenosine and deoxyadenosine inhibition of human lymphocyte activation | |
| CA2419399A1 (en) | Nucleoside derivatives for the treatment of hepatitis c | |
| Sanghvi et al. | Antitumor and antiviral activity of synthetic. alpha.-and. beta.-ribonucleosides of certain substituted pyrimido [5, 4-d] pyrimidines: a new synthetic strategy for exocyclic aminonucleosides | |
| DK468288A (da) | Antivirale forbindelser | |
| SE9502474D0 (sv) | Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa | |
| Ray | Intracellular interactions between nucleos (t) ide inhibitors of HIV reverse transcriptase | |
| Piper et al. | Biochemical basis for the differential sensitivity of human T-and B-lymphocyte lines to 5-fluorouracil | |
| EP0334361A3 (en) | Novel acetylenic, cyano and allenic aristeromycin/adenosine derivatives | |
| Pisarev et al. | Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication | |
| IE831386L (en) | Pharmaceutical compositions based on xylosides and lyxosides¹of purine and pyrimidine bases | |
| DK0720604T3 (da) | Konformationelt låste nukleosidanaloger | |
| Leoutsakos et al. | The effect of adenosine and its analogues on cyclic AMP changes and histamine secretion from rat peritoneal mast cells stimulated by various ligands | |
| Montgomery | The design of chemotherapeutic agents | |
| BR0016162A (pt) | Composições e métodos para l-nucleosìdeos, lnucleotìdeos e seus análogos | |
| Törnevik et al. | 2', 3'-Dideoxycytidine toxicity in cultured human CEM T lymphoblasts: effects of combination with 3'-azido-3'-deoxythymidine and thymidine. | |
| Diamantstein et al. | Regulation of DNA synthesis by guanosine-5′-diphosphate, cyclic guanosine-3′, 5′-monophosphate, and cyclic adenosine-3′, 5′-monophosphate in mouse lymphoid cells |